Your browser is no longer supported. Please, upgrade your browser.
Settings
PFE Pfizer Inc. daily Stock Chart
PFE [NYSE]
Pfizer Inc.
IndexDJIA S&P500 P/E30.40 EPS (ttm)1.13 Insider Own0.04% Shs Outstand6.10B Perf Week0.94%
Market Cap209.03B Forward P/E12.94 EPS next Y2.65 Insider Trans-30.91% Shs Float6.06B Perf Month-1.61%
Income6.99B PEG4.66 EPS next Q0.62 Inst Own71.90% Short Float0.65% Perf Quarter1.69%
Sales52.29B P/S4.00 EPS this Y-21.50% Inst Trans-3.06% Short Ratio1.98 Perf Half Y17.04%
Book/sh10.34 P/B3.31 EPS next Y7.56% ROA4.20% Target Price39.53 Perf Year8.53%
Cash/sh3.43 P/C9.98 EPS next 5Y6.52% ROE10.90% 52W Range27.77 - 37.08 Perf YTD9.06%
Dividend1.20 P/FCF34.56 EPS past 5Y1.60% ROI7.30% 52W High-7.61% Beta0.86
Dividend %3.50% Quick Ratio1.10 Sales past 5Y-5.60% Gross Margin77.80% 52W Low23.38% ATR0.45
Employees97900 Current Ratio1.40 Sales Q/Q-42.10% Oper. Margin17.60% RSI (14)44.00 Volatility1.24% 1.23%
OptionableYes Debt/Eq0.70 EPS Q/Q-58.80% Profit Margin13.40% Rel Volume0.65 Prev Close34.15
ShortableYes LT Debt/Eq0.49 EarningsOct 25 BMO Payout101.70% Avg Volume19.93M Price34.26
Recom2.20 SMA20-0.53% SMA50-2.70% SMA2005.28% Volume12,937,001 Change0.32%
Jun-20-16Reiterated Jefferies Buy $42 → $40
May-12-16Initiated Berenberg Hold $38
May-04-16Reiterated UBS Buy $36 → $38
Apr-18-16Resumed Goldman Neutral $35
Apr-07-16Resumed Morgan Stanley Equal-Weight $35
Apr-07-16Resumed JP Morgan Overweight $38
Nov-25-15Upgrade Sun Trust Rbsn Humphrey Reduce → Neutral
Nov-03-15Reiterated Argus Buy $41 → $46
Oct-28-15Reiterated Deutsche Bank Buy $41 → $43
Oct-02-15Upgrade Morgan Stanley Equal-Weight → Overweight $35 → $38
Jul-29-15Reiterated Argus Buy $39 → $41
Jun-17-15Initiated Piper Jaffray Overweight
Apr-30-15Reiterated Argus Buy $36 → $39
Apr-29-15Downgrade Citigroup Buy → Neutral
Jan-28-15Reiterated Argus Buy $35 → $36
Dec-18-14Reiterated Deutsche Bank Buy $34 → $35
Jul-02-13Downgrade Standpoint Research Hold → Sell $24
Apr-15-13Reiterated Barclays Equal Weight $25 → $32
Jan-30-13Reiterated UBS Buy $29 → $31
Jan-30-13Reiterated Argus Buy $28 → $32
Sep-23-16 07:04PM  Generics or Specialty: Which Mylan Segment Is Growing Fastest?
05:25PM  Tevas Valuation Multiples Compared to Other Generic Drug Players
04:17PM  The 5 Highest Dividend Payout Ratios on the Dow at Motley Fool
04:07PM  Axovant Confidence 'Not Swayed' After Rival Alzheimer's Drug Fails
02:12PM  Dow 30 Stock Roundup: Microsoft Rewards Shareholders; GE Wins $1.9B Nuclear Power Contract
10:01AM  Novartis (NVS) Zykadia Positive in Phase III ASCEND-4 Study
09:28AM  [video]Takeover Chatter Around Clovis May Be Overdone
08:30AM  Pfizer Announces Expiration of HSR Waiting Period For Proposed Acquisition of Medivation Business Wire
08:03AM  Better Buy: Pfizer Inc. vs. Johnson & Johnson at Motley Fool
08:00AM  Pharma Stock Roundup: Allergan Acquisitions in Focus, J&J to Buy Abbott's AMO
07:29AM  UPDATE 1-Novartis's Zykadia gets positive results, faces Roche pressure Reuters
Sep-22-16 01:43PM  Lundbeck says Alzheimer's late-stage study fails Reuters
11:56AM  Pfizer Declares 30-Cent Fourth-Quarter 2016 Dividend Business Wire
Sep-21-16 04:32PM  'Blockbuster Franchises' Spark M&A Fever For Sarepta, Ariad, Biotechs
03:13PM  [$$] Big Pharma's Big Checkbooks Drive Biotech Resurgence at The Wall Street Journal
10:04AM  How Procysbi Fits into Horizons Existing Orphan Drug Portfolio
Sep-20-16 05:09PM  This ETF bets that companies with female leadership will outperform at MarketWatch
01:30PM  This Hated Pharma Stock Has A Bright Future
10:00AM  Pfizer Invites Public To View And Listen To Webcast Of November 1 Conference Call With Analysts Business Wire
09:50AM  5 Dividend Paying Stocks Deutsche Bank Likes If Trump Wins in November at 24/7 Wall St.
08:29AM  [$$] Incoming GSK chief faces challenge to maintain momentum at Financial Times
08:08AM  [$$] Big pharma targets drug-resistant superbugs at Financial Times
06:50AM  Pfizer (PFE) Breast Cancer Drug Ibrance Wins CHMP Backing
Sep-19-16 07:26PM  Stocks Trade Lower Monday With Global Central Bank Uncertainty
06:56PM  How To Predict The Next Sarepta (FDA Approval Stock) And Win Big at Forbes
06:50PM  A Breakdown Here In This Sector Would Not Be Healthy
03:57PM  Pfizer: Hospira Is Future; Xtandi Is Today's Meal
09:25AM  Pfizers on a Roll, Netflix Earns the Ire of Fox, Plus 2 Other Trending Stories at Insider Monkey
07:34AM  GSK cuts vaccine price for refugees, bowing to pressure
Sep-18-16 12:38PM  GoPro, Oracle, Pfizer, and More: Traders Cant Stop Watching These Stocks This Weekend at Insider Monkey
Sep-17-16 11:41AM  Is This New Market the Biggest Investment Idea of the Decade? at Motley Fool
Sep-16-16 05:24PM  Pfizer Announces Positive Top-Line Results from REFLECTIONS B537-02 Study for PF-06438179 (infliximab-Pfizer) a Potential Biosimilar to Remicade® (infliximab) Business Wire
02:08PM  Kahn Brothers Trims Pfizer, Citigroup
01:28PM  Inside the FDA: Why The Pfizer, Inc. (PFE) Boxed Warning On Chantix Is Unlikely To Be Removed at Insider Monkey
11:21AM  CEOs say consumers are less confident
09:19AM  Blog Coverage Aerie Pharma Glaucoma Drug Roclatan Surpasses Primary Goals at End Phase III Trials
09:10AM  EMA panel recommends nod for Pfizer's breast cancer drug Reuters
09:04AM  Pharma Stock Roundup: Acquisitions & Deals Pick Up Pace, Aerie Up on Positive Data
09:03AM  Merck/Pfizer Diabetes Drug Ertugliflozin Positive in Phase III
08:50AM  The Top 10 S&P 500 Dividend Stocks to Buy Now at Kiplinger
07:24AM  Pfizer Receives Positive CHMP Opinion For IBRANCE® (palbociclib) In Combination With Endocrine Therapy For The Treatment Of HR+/HER2- Metastatic Breast Cancer In Europe Business Wire
Sep-15-16 03:39PM  Merck (MRK) Stock Higher, Joint Pfizer Diabetes Drug Meets Primary Endpoint
11:32AM  FDA Panel Suggests Removing Warning from Pfizer's Chantix
09:13AM  Better Buy: Pfizer Inc. vs. AbbVie Inc. at Motley Fool
09:07AM  Pfizer's (PFE) Chantix Warning Could Be Removed After FDA Recommendation
08:56AM  FDA AdCom Votes on Pfizer and Spectrum Drugs - What Next?
08:41AM  Merck and Pfizer's diabetes treatment meets primary endpoint of late-stage trial at MarketWatch
08:31AM  Merck and Pfizer Announce Investigational Ertugliflozin Met Primary Endpoint of A1C Reduction When Added to Sitagliptin and Metformin in People with Type 2 Diabetes Business Wire
08:00AM  PARP Wars: Biotech M&A's New Hope at Bloomberg
07:58AM  Wells Fargo, Twitter, Pfizer and More: Why Investors Are Yammering About These 5 Stocks at Insider Monkey
07:57AM  Early movers: AAPL, UTX, SNE, MC, WYNN, BA, PFE, OZM, PSX, DKS & more at CNBC
Sep-14-16 07:47PM  [$$] Pfizer Moves Closer to FDA Removal of Suicide Warning on Chantix at The Wall Street Journal
07:35PM  FDA panel recommends dropping serious warning on Pfizer's Chantix Reuters
06:14PM  FDA Advisory Committees Recommend to Remove Boxed Warning in Labeling for Pfizers Smoking Cessation Therapy, CHANTIX® (varenicline) Business Wire
08:42AM  Why Pfizer's Stock Is a Big Gamble Right Now at Motley Fool
08:25AM  Fed Wont Raise Until December: Buy These 4 Dividend Blue Chips On Sale at 24/7 Wall St.
06:01AM  Here's Why Pfizer Is Headed Lower Before It Can Head Higher
Sep-13-16 09:57PM  [$$] Takeda earmarks $15bn for US pharma acquisitions at Financial Times
03:27PM  Pfizer (PFE) Stock Falls, Jefferies Drops Price Target
03:01PM  3 Dividend Stocks to Buy in a Market Crash at Motley Fool
01:46PM  Insight from Ray Dalio and Tim Geithner on the Credit Market
01:32PM  Why Gilead Sciences Loves PARPAnd You Should Too at Barrons.com
01:20PM  Big Pharma Spends Millions to Keep Prices High for California Agencies
10:46AM  Doctors Downplaying Drugs Suicide Risks Attract FDAs Scrutiny at Bloomberg
10:04AM  GlaxoSmithKline Giving a Shot to Its Vaccines Business
10:00AM  Pfizer Launches New Moodivator App to Help Support, Encourage and Motivate People with Depression Business Wire
08:04AM  Product Launches Are Part of Biogens Plans to Boost Revenues
07:25AM  Major Pharma Continues to See Significant Drop in Short Interest at 24/7 Wall St.
Sep-12-16 01:30PM  5 Undervalued Dividend Stocks To Protect Your Portfolio
11:59AM  Is Clovis Oncology Still a Strong Buy? at Motley Fool
11:49AM  This Forbes 'Most Innovative' Growth Stock Remains Near Buy Point
11:26AM  Will Pfizer (PFE) Stock Be Affected by FDA Chantix Study Scrutiny?
10:29AM  FDA Staff Question Pfizers Psychiatric Data on Chantix at Bloomberg
10:13AM  Better Buy: Merck & Co., Inc. vs. Pfizer at Motley Fool
10:13AM  2 Biotech Stocks that Turned $8,000 into over $250,000 at Motley Fool
10:04AM  How Can Pfizer Revive Its Essential Health Business?
09:10AM  FDA staff flags concerns about Pfizer's quit-smoking drug study Reuters
08:18AM  Gilead Sciencs, Inc. a Takeover Target? It's Not as Crazy As It Sounds at Motley Fool
08:05AM  Pfizers Hospira Deal: Catching Up a Year Later
Sep-11-16 05:09PM  Reads For The Weed-Kend: Marijuana Roadside Testing, Pregnancy And Depression
Sep-10-16 08:01AM  Pfizer Takes Aim at Johnson & Johnson at Motley Fool
Sep-09-16 06:04PM  Why Is Pfizers Legacy Brand Portfolio Falling?
05:00PM  Five Dividend Stocks Billionaires Like at Insider Monkey
04:34PM  Teva Discusses EpiPen Comps as Host of Generics Unveiled
04:19PM  Pfizers Essential Health Business: What You Need to Know
03:46PM  Gilead Sciences: What is PARP? at Barrons.com
12:37PM  What Are Analysts Recommendations for Perrigo in 2016?
11:28AM  Clinton spokeswoman defends drug plan after Pfizer comments
10:58AM  Pfizer CEO: Clinton's plan to curb high drug prices would be 'very negative for innovation'
10:25AM  Medivation (MDVN) Scales New 52-Week High on Pfizer Deal
Sep-08-16 04:49PM  Clovis Oncology Up As FDA Skips Review Panel For New Drug
03:28PM  [$$] Chrono Therapeutics Raises $47.6M Series B for Smoking-Cessation Tech at The Wall Street Journal
02:18PM  Pfizer CEO says Clinton plan to curb drug prices would hurt consumers Reuters
01:08PM  Is Pfizer About to Slash Its Dividend? at Motley Fool
12:46PM  Clintons Drug Proposals Very Negative, Pfizer CEO Says
11:39AM  5 Dividend Stocks to Put on Your Shopping List at Motley Fool
11:29AM  Merck's Lung Cancer Drug Keytruda Under Priority Review
10:45AM  [$$] Funding Snapshot: Immune-Drug Developer AnTolRx Raises $4M Series A at The Wall Street Journal
09:49AM  One Of Forbes' 'Most Innovative Growth Companies' Nears Breakout
09:07AM  AnTolRx, Inc. Announces Series A Equity Funding from Pfizer, JDRF and Orion Equity Partners, LLC to Develop Targeted Nanoparticle Tolerance Therapeutics PR Newswire
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops and commercializes medicines for various therapeutic areas, including inflammation/immunology, cardiovascular/metabolic, neuroscience/pain, and rare diseases. The VOC segment develops and commercializes vaccines, as well as products for oncology and consumer healthcare. It provides over-the-counter products comprising dietary supplements under the Centrum, Caltrate, and Emergen-C brands; pain management products under the Advil and ThermaCare brands; gastrointestinal products under the Nexium 24HR/Nexium Control and Preparation H brands; and respiratory and personal care products under the brand names of Robitussin, Advil Cold & Sinus, Advil Sinus Congestion Relief & Pain, Dimetapp, and ChapStick. The GEP segment offers products that have lost marketing exclusivity in various markets; and branded generics, generic sterile injectable products, biosimilars, infusion systems, and other products. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. It has licensing agreements with Cellectis SA and AstraZeneca PLC; and collaborative agreements with Eli Lilly & Company, OPKO Health, Inc., BioRap Technologies LTD., and Merck KGaA. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DAMELIO FRANK AExecutive Vice PresidentMay 26Option Exercise24.43100,0002,443,000472,994May 27 11:03 AM
DAMELIO FRANK AExecutive Vice PresidentMay 26Sale34.49100,0003,449,115372,994May 27 11:03 AM
CANGIALOSI LORETTA VSr. Vice President, ControllerMay 24Option Exercise25.8786,0002,224,820271,663May 26 10:07 AM
CANGIALOSI LORETTA VSr. Vice President, ControllerMay 24Sale33.9786,0002,921,147185,663May 26 10:07 AM
YOUNG JOHN DGroup PresidentMay 10Option Exercise25.8741,7001,078,779200,399May 11 06:04 PM
DAMELIO FRANK AExecutive Vice PresidentMay 10Option Exercise24.43192,0004,690,560564,994May 11 06:04 PM
YOUNG JOHN DGroup PresidentMay 10Sale33.5341,7001,398,277158,699May 11 06:04 PM
DAMELIO FRANK AExecutive Vice PresidentMay 10Sale33.66192,0006,462,579372,994May 11 06:04 PM
READ IAN CChairman & CEOMay 09Option Exercise25.74275,0007,078,2501,471,738May 11 06:03 PM
SUSMAN SALLYExecutive Vice PresidentMay 09Option Exercise22.2823,884532,136199,735May 11 04:35 PM
HILL CHARLES HExecutive Vice PresidentMay 09Sale33.8429,6001,001,65160,828May 11 04:35 PM
SUSMAN SALLYExecutive Vice PresidentMay 09Sale33.7167,8842,288,669131,851May 11 04:35 PM
READ IAN CChairman & CEOMay 09Sale33.80275,0009,295,0391,196,738May 11 06:03 PM
SUSMAN SALLYExecutive Vice PresidentMay 05Option Exercise22.2856,0161,248,036231,867May 06 09:51 AM
SUSMAN SALLYExecutive Vice PresidentMay 05Sale33.7156,0161,888,144175,851May 06 09:51 AM
SUSMAN SALLYExecutive Vice PresidentMay 04Option Exercise22.2820,100447,828195,951May 06 09:51 AM
SUSMAN SALLYExecutive Vice PresidentMay 04Sale33.8720,100680,762175,851May 06 09:51 AM
DAMELIO FRANK AExecutive Vice PresidentMay 03Sale33.6587,0792,930,208372,994May 05 05:27 PM
Lewis-Hall Freda CExecutive Vice PresidentFeb 24Option Exercise18.90110,9812,097,541274,756Feb 26 03:05 PM
MADDALUNA ANTHONY JExecutive Vice PresidentFeb 24Option Exercise18.9062,4531,180,362140,772Feb 26 03:05 PM
OLSON LAURIE JExecutive Vice PresidentFeb 24Option Exercise18.9018,984358,79889,467Feb 26 03:05 PM
READ IAN CChairman & CEOFeb 24Option Exercise18.90584,11211,039,7172,030,151Feb 26 03:05 PM
SUSMAN SALLYExecutive Vice PresidentFeb 24Option Exercise18.90110,9812,097,541263,151Feb 26 03:05 PM
YOUNG JOHN DGroup PresidentFeb 24Option Exercise18.9052,570993,573188,679Feb 26 03:05 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 24Option Exercise18.9034,171645,832210,943Feb 26 03:05 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 24Option Exercise18.90210,2803,974,292622,467Feb 26 03:05 PM
Dolsten MikaelPresident R&DFeb 24Option Exercise18.90210,2803,974,292577,902Feb 26 03:05 PM
HILL CHARLES HExecutive Vice PresidentFeb 24Option Exercise18.9078,8551,490,360149,135Feb 26 03:05 PM
JOHNSON RADY AExecutive Vice PresidentFeb 24Option Exercise18.9019,188362,65366,048Feb 26 03:05 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 24Option Exercise18.9034,171645,832149,482Feb 26 03:05 PM
BOURLA ALBERTGroup PresidentFeb 24Option Exercise18.9030,666579,587144,675Feb 26 03:03 PM
BOURLA ALBERTGroup PresidentDec 15Option Exercise26.2030,000786,000140,560Dec 16 06:46 PM
YOUNG JOHN DGroup PresidentDec 14Option Exercise26.2031,500825,300163,999Dec 16 06:55 PM
PFIZER INC10% OwnerOct 06Buy7.00714,2854,999,9952,253,509Oct 07 05:42 PM